Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + gemcitabine + docetaxel
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intravesical
01
Overview
This combination regimen consists of systemic **pembrolizumab** (an anti-PD-1 monoclonal antibody) and intravesical chemotherapy using **gemcitabine** and **docetaxel**. It is specifically being investigated for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to or have been exposed to Bacillus Calmette-Guérin (BCG) therapy. Pembrolizumab works by blocking the PD-1/PD-L1 pathway to enhance the immune response against tumor cells, while gemcitabine and docetaxel provide local cytotoxic effects within the bladder. The regimen is currently being evaluated in a Phase II study sponsored by the Bladder Cancer Latin American Group (BLATAM).
- Brand names
- KeytrudaGemzarTaxotere
- Other names
- Gemcitabine/Docetaxel + PembrolizumabGem/Doce + Pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on pembrolizumab + gemcitabine + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + gemcitabine + docetaxel.